Breast Cancer News
In this section, access cutting-edge news about breast cancer in young women including treatment updates, emerging therapies, study results and other medical and quality-of-life issues important to you.
A study of North Carolinian women found that young African-American women were far more likely to have breast cancer treatment delay than White women in the same age range of 20 to 49.
Each December, medical experts and researchers from around the world meet at the 5-day San Antonio Breast Cancer Symposium to share the latest findings from breast cancer clinical trials. Read on for updates from the 2013 symposium, held December 10–14.
NEW YORK (Reuters Health) - Poor young women are more likely to delay going to the doctor when they find a breast lump than women in better financial straits, a new study suggests.
Researchers surveyed young breast cancer patients about how they first discovered their cancer, how long they waited to see a doctor and how long after diagnosis they started treatment.
Young African-American women with breast cancer report more symptoms of depression than their healthy peers, even when they have good social support systems and an ability to adapt to new environments or situations, a study published in the Journal of Cancer Survivorship shows.
NEW YORK (Reuters Health) - Young women with breast cancer often overestimate both their chance of developing cancer in the other breast and how much removal of that breast is likely to protect them, a new U.S. study suggests.
Women age 40 or younger when diagnosed with early-stage, HER2-positive breast cancer do not have an increased risk of early recurrence due to age. They also are as likely as older women to benefit from treatment with trastuzumab, or Herceptin, according to a recent study.
NEW YORK (Reuters Health) - Although recommendations differ on when women should start getting screened for breast cancer, a new study suggests women in their 40s may benefit from yearly mammograms.
A study of about 7,000 women treated with tamoxifen for early-stage, ER+ breast cancer showed lower recurrence and mortality rates for those who took the medication for 10 years instead of 5 years. This research, which has not yet been published, reinforces the findings of the international ATLAS trial.
Young women whose surgery-only breast cancer treatment is delayed longer than 6 weeks have decreased survival rates compared with women who are treated sooner.
Young women who have a choice of surgical treatment choose mastectomy more often than lumpectomy, or breast-conserving treatment, according to a study presented at a major breast cancer conference.